PHOENICIA BIOSCIENCES, INC.

Basic Information

45 Beaver Rd
WESTON, MA, 02493-1017

Company Profile

n/a

Additional Details

Field Value
DUNS: 808428689
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: n/a


  1. Topical Therapeutic to Promote Healing of Chronic Wounds

    Amount: $219,306.00

    DESCRIPTION (provided by applicant): Chronic refractory, or non-healing, wounds or ulcerations of the extremities represent a major medical condition affecting millions of patients. A chronic wound is ...

    STTR Phase I 2013 Department of Health and Human Services
  2. Next Generation Therapeutics for Hemoglobinopathies

    Amount: $491,254.00

    DESCRIPTION (provided by applicant): Sickle cell disease and 2-thalassemias are mankind's most common hereditary monogenic diseases, comprise a major global health burden, and cost the US healthc ...

    STTR Phase I 2012 Department of Health and Human Services
  3. Virus-Targeted Therapy for Malignancies

    Amount: $288,895.00

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. in vivo Studies of Clinical Stage Globin Modulators

    Amount: $304,344.00

    DESCRIPTION (provided by applicant): Inherited disorders which decrease production or alter structure of the 2-chain of hemoglobin A (2-thalassemias or sickle cell disease) are among the most common m ...

    STTR Phase I 2011 Department of Health and Human Services
  5. Oral Agents to Stimulate Neutrophil Production

    Amount: $350,566.00

    DESCRIPTION (provided by applicant): Phoenicia Biosciences, Inc. scientists have discovered a small family of low MW compounds (short-chain fatty acid derivatives (SCFADs) - designated Hemokines ) th ...

    STTR Phase I 2010 Department of Health and Human Services
  6. Development of an Oncogene-Targeted Therapeutic

    Amount: $271,227.00

    DESCRIPTION (provided by applicant): The concept of targeting cancer therapeutics towards specific mutations or abnormalities in tumor cells which are not found in normal tissues has the potential adv ...

    STTR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government